Home News

First nine months 2020 results presentation

Operating income, growth figures, profitability and how our products have behaved.

Thu, 05/11/2020 - 00:00 0 min
Download related document
No votes yet
 
Related
ROVI and Moderna Announce Collaboration for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate
ROVI and Moderna Announce Collaboration for Outside the United States Fill-...
Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a...
3 min
09/07/2020
First quarter 2020 results presentation
0 min
13/05/2020
ROVI reports operating revenue growth of 23% and EBITDA growth of 68%
ROVI reports operating revenue growth of 23% and EBITDA growth of 68%
Operating revenue increased by 23% to 101.0 million euros in the first quarter of 2020, mainly driven by the strength of the specialty...
7 min
13/05/2020